GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » OncoCyte Corp (NAS:OCX) » Definitions » Degree of Operating Leverage

OCX (OncoCyte) Degree of Operating Leverage : 0.26 (As of Mar. 2025)


View and export this data going back to 2015. Start your Free Trial

What is OncoCyte Degree of Operating Leverage?

Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. OncoCyte's Degree of Operating Leverage for the quarter that ended in Mar. 2025 was 0.26. The higher Degree of Operating Leverage, the higher operating risk the company will take.

The industry rank for OncoCyte's Degree of Operating Leverage or its related term are showing as below:

OCX's Degree of Operating Leverage is ranked better than
53.14% of 207 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.45 vs OCX: 0.26

OncoCyte Degree of Operating Leverage Historical Data

The historical data trend for OncoCyte's Degree of Operating Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoCyte Degree of Operating Leverage Chart

OncoCyte Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Degree of Operating Leverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.87 1.29 1.30 5.74

OncoCyte Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Degree of Operating Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.36 -81.21 -16.51 5.74 0.26

Competitive Comparison of OncoCyte's Degree of Operating Leverage

For the Diagnostics & Research subindustry, OncoCyte's Degree of Operating Leverage, along with its competitors' market caps and Degree of Operating Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OncoCyte's Degree of Operating Leverage Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, OncoCyte's Degree of Operating Leverage distribution charts can be found below:

* The bar in red indicates where OncoCyte's Degree of Operating Leverage falls into.


;
;

OncoCyte Degree of Operating Leverage Calculation

OncoCyte's Degree of Operating Leverage for the quarter that ended in Mar. 2025 is calculated as:

Degree of Operating Leverage=% Change in EBIT**/% Change in Revenue
=( -58.107 (Mar. 2025) / -39.887 (Mar. 2024) - 1 )/( 3.843 (Mar. 2025) / 1.382 (Mar. 2024) - 1 )
=0.4568/1.7808
=0.26***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EBIT and Revenue was used to calculate Degree of Operating Leverage.
*** Please be aware that the Degree of Operating Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


OncoCyte  (NAS:OCX) Degree of Operating Leverage Explanation

Degree of Operating Leverage (DOL) is a leverage ratio that measures the sensitivity of a company’s operting income, also referred to as Earnings Before Interest and Taxes (EBIT), to fluctuations in its Revenue. DOL is a method used to quantify a company’s operating risk. This risk is related to the company's structure of variable costs and fixed costs. Since the fixed costs do not allow the company to adjust the operating costs, the operating risk rises with a higher fixed-to-variable costs proportion.

A high Degree of Operating Leverage indicates that the company’s fixed costs exceed its variable costs. By increasing the sales, the company can earn more profits. In addition, the company must be able to maintain relatively high sales to cover all fixed costs.

Be Aware

The use of operating leverage varies across different industries and business sectors, and the application of Degree of Operating Leverage (DOL) should be adjusted accordingly.


OncoCyte Degree of Operating Leverage Related Terms

Thank you for viewing the detailed overview of OncoCyte's Degree of Operating Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


OncoCyte Business Description

Traded in Other Exchanges
Address
15 Cushing, Irvine, CA, USA, 92618
OncoCyte Corp is a pioneering diagnostics technology company. Its mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers, or payers.
Executives
Broadwood Partners Lp 10 percent owner BROADWOOD CAPITAL INC., 142 WEST 57TH STREET, 11TH FLOOR, NEW YORK NY 10019
Andrew Arno director C/O MERRIMAN CURHAN FORD GROUP, INC., 600 CALIFORNIA STREET, 9TH FLOOR, SAN FRANCISCO CA 94108
Josh Riggs officer: Interim CEO 15 CUSHING, IRVINE CA 92618
John Peter Gutfreund other: Former Director 767 5TH AVENUE, 44TH FLOOR, NEW YORK NY 10153
Alfred D Kingsley director 150 E 57TH STREET, NEW YORK NY 10022
Pura Vida Investments, Llc 10 percent owner 512 W 22ND STREET, 7TH FLOOR, NEW YORK NY 10011
Lou Silverman director
James Yang Liu officer: Controller, PAO C/O ONCOCYTE CORPORATION, 15 CUSHING, IRVINE CA 92618
Andrew J. Last director 3420 CENTRAL EXPRESSWAY, SANTA CLARA CA 95051
Jennifer L. Carter director C/O DFP SPONSOR LLC, 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Ronald Asbury Andrews director 5791 VAN ALLEN WAY, CARLSBAD CA 92008
Melinda Griffith director 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Anish M. John officer: SVP, Finance, and Interim CFO C/O ONCOCYTE CORPORATION,, 15 CUSHING, IRVINE CA 92618
Li Yu officer: VP Cntrllr/Prncpl Acctng Offcr 120 NEWPORT CENTER DRIVE., NEWPORT BEACH CA 92660
Efrem Kamen 10 percent owner C/O PURA VIDA INVESTMENTS, LLC, 512 W 22ND STREET, 7TH FLOOR, NEW YORK NY 10011